

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in





Anti-DPGA anthrax [F24F2] Bulk Size Ab03885-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG3 format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent[™], Kappa

Clone Number: F24F2

Alternative Name(s) of Target: DPGA; capsular antigen; γDPGA; gamma DPGA; poly-gamma-d-glutamic

acid; poly-γ-d-glutamic acid; antiphagocytic polypeptide capsule

UniProt Accession Number of Target Protein:

Published Application(s): ICC, ELISA, IHC

Published Species Reactivity: Bacillus anthracis

Immunogen: The original antibody was generated by immunizing BALB/c mice with B. licheniformis γDPGA in combination with CD40 agonist antibody.

Specificity: This antibody specifically binds the poly- γ -D-glutamic acid (γ DPGA) capsule of Bacillus anthracis. Bacillus anthracis is surrounded by an antiphagocytic polypeptide capsule composed of poly γ -d-glutamic acid (γ DPGA). The γ DPGA capsule shields the vegetative form of B. anthracis from agglutination by monoclonal antibodies to its cell wall polysaccharide. γ DPGA has been identified recently as a potential target for vaccine development. Bacillus anthracis is a spore-forming bacterium and a causative agent for Anthrax, which is a highly lethal infectious disease in human and poses a great threat as an emerging bioterror agent.

Application Notes: This antibody was used for development of a quantitative capture ELISA for PDGA (PMID: 18195035). A 50:50 mixture of PDGA antibodies F24F2 and F26G3 was used in the development of an antigen capture ELISA with a sensitivity of approximately 9 ng/ml of serum after a 1/40 dilution and 2.25 ng/ml for a 1:10 dilution (PMID: 19506008). The HRP or Alexa Fluor 555 labelled antibody was also used in the immunohistochemical staining of γ DPGA in mouse liver and spleen tissues after they were injected with 500, 100, or 20µg of γ DPGA and tissues were harvested on days 1, 2, 4, and 8 (PMID: 18195035). This antibody was also used in the cellular localization of γ DPGA in mouse liver (PMID: 18195035).

Antibody First Published in: Kozel et al. MAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc Natl Acad Sci U S A. 2004 Apr 6; 101(14): 5042–5047.

PMID:15051894

Note on publication: Describes the generation of two antibodies against B. anthracis γ DPGA and evaluates their capacity to provide protection in pulmonary mouse model of anthrax.

Product Form

Size: 1 mg Purified antibody in bulk size. **Purification:** Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer

storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.